vobarilizumab (ALX-0061) / Sanofi - LARVOL DELTA

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. (PubMed, Ann Rheum Dis) - "This SLR informed the task force regarding the evidence base of various therapeutic regimen for the development of the update of EULAR's RA management recommendation."

Clinical • Journal • Immunology • Rheumatoid Arthritis • Rheumatology

Study to assess safety and efficacy of anti-interleukin 6-receptor (IL6R) nanobody in rheumatoid arthritis (RA) patients (clinicaltrials.gov) - P1/2, N=72; Recruiting -> Active, not recruiting

Enrollment closed • Immunology • Rheumatoid Arthritis

Ablynx 2011 annual results (Ablynx) - P2 POC data anticipated in H2 2012

Anticipated P2 data • Immunology • Rheumatoid Arthritis

Ablynx announces 2016 full year results (Ablynx Press Release) - "During H1 2017, Ablynx expects to hold scientific advice and 'end-of-Phase II' meetings with regulators in Europe and the USA to discuss its Phase IIb results with vobarilizumab in RA and plans for a Phase III programme...Ablynx will continue to explore the possibility of a new partnership which would be needed to support further clinical development of this molecule in RA."

Anticipated licensing / partnership • Anticipated new P3 trial • Anticipated regulatory • Immunology • Rheumatoid Arthritis

RESULTS OF A PHASE 2B STUDY OF VOBARILIZUMAB, AN ANTI-INTERLEUKIN-6 RECEPTOR NANOBODY, AS MONOTHERAPY IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS (EULAR 2017) - " Patients with active RA who were intolerant to methotrexate (MTX) or for whom continued MTX treatment was inappropriate were randomized in a 1:1:1:1 ratio to 1 of the 3 blinded dose groups of vobarilizumab or to open-label tocilizumab (TCZ), all of which were given subcutaneously. In patients with active RA, treatment with vobarilizumab monotherapy had a positive impact on disease activity with no unexpected safety findings."

Adverse events • Clinical • Monotherapy • P2 data • Biosimilar • Immunology • Inflammation • Rheumatoid Arthritis

Assessment of Dose Dependent Effects of Vobarilizumab, an Anti-IL6 Receptor (IL-6R) Nanobody®, on Systemic Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis (RA): Results of Two Phase 2b Studies (ACR-ARHP 2017) - "...Main efficacy and safety results of both RA phase 2b studies with vobarilizumab when used in combination with methotrexate (ALX0061-C201) and as monotherapy (ALX0061-C202) were previously reported (ref 1 and 2)...An open-label tocilizumab (TCZ) arm was included to obtain parallel descriptive information... The observed dose dependent PD biomarker responses and effects on cartilage degradation and joint inflammation biomarkers further support the strong potential for disease modifying activity of vobarilizumab in RA."

Biomarker • Clinical • Combination therapy • P2 data • Immunology • Inflammation • Lupus • Rheumatoid Arthritis

Ablynx initiates Phase II SLE study with its anti-IL-6R nanobody, partnered with Abbvie (Ablynx Press Release) - P2, N=300; NCT02437890; Sponsor: Ablynx; "Ablynx...today announced that it has administered the first dose in the Phase II STEADY study to evaluate the efficacy and safety of its anti-IL-6R Nanobody®, ALX-0061, administered subcutaneously in adult patients with moderate to severe, active seropositive SLE...'The efficacy and safety of this novel anti-IL-6R Nanobody is currently being evaluated in multiple Phase II studies with results from the RA studies anticipated in the second half of 2016 and SLE in 2018.' "

Anticipated P2 data • Trial initiation date • Immunology • Lupus • Rheumatoid Arthritis

Ablynx: Corporate Presentation (Ablynx) - Anticipated initiation of P1 SC safety study for rheumatoid arthritis in 2014; Anticipated initiation of P2b trial for rheumatoid arthritis in 2015; Anticipated top line results from P2b trial for rheumatoid arthritis in 2016

Anticipated new P1 trial • Anticipated new P2b trial • Anticipated P2b data • Immunology • Rheumatoid Arthritis

Biotech group Ablynx sells 100 mln euros of convertibles (Reuters) - “…Ablynx sold 100 million euros ($111 million) of convertible bonds on Wednesday to fund its research and further tests of experimental drugs…. Ablynx also aimed to drive forward jointly owned projects, such as rheumatoid arthritis drug ALX-0061 which it is developing with partner AbbVie”

Clinical • Immunology • Lupus • Rheumatoid Arthritis

Ablynx: Corporate Presentation (Ablynx) - Anticipated initiation of P2b trial for rheumatoid arthritis in 2015; Anticipated data from P2 trial for rheumatoid arthritis in 2016

Anticipated P2 data • Anticipated trial initiation date • Rheumatoid Arthritis

ALX-0061 phase I bioavailability study in healthy volunteers (clinicaltrials.gov) - P1, N=70; Sponsor: Ablynx; Not yet recruiting -> Recruiting.

Enrollment open • Immunology • Lupus • Rheumatoid Arthritis

Ablynx: Corporate Presentation (Ablynx) - "ALX-0061 - compelling Phase IIa results in RA patients"; "Treatment was highly efficacious and was well tolerated at all doses"; "No increase of adverse events upon extension of treatment"; "No anti-drugs antibodies were reported"

P2a data • Rheumatoid Arthritis

Ablynx: J.P. Morgan Healthcare Conference (Ablynx) - Anticipated patent expiry including extensions in 2032/2033

Anticipated patent expiry • Immunology • Rheumatoid Arthritis

Ablynx: Corporate Presentation (Ablynx) - Anticipated initiation of P2 trial (NCT02437890) in SLE in mid-2015; Anticipated top-line data from P2 trial (NCT02437890) in SLE in 2018

Anticipated P2 data • Anticipated trial initiation date • Immunology

Impact of clinical remission on physical function in patients with rheumatoid arthritis treated with ALX-0061: Post-hoc analysis of phase I/II data (ACR-ARHP 2014) - Presentation time: Monday, November 17, 2014; 8:30AM–4:00PM; Abstract #1479; P1/2, N=37; Sponsor: Ablynx; NCT01284569; “At week 24, 62.5% (15/24) of pts treated with ALX-0061 achieved DAS28_2.6 remission, while remission using the more stringent Boolean criteria was observed in 29.2% (7/24) of the pts....between 12 and 24 wks, approximately one third, i.e. 37.5% and 29.2%, of pts treated with ALX-0061 remained in DAS28 remission during the last 3 (at wks 16, 20, and 24) and 4 (at wks 12, 16, 20, and 24) consecutive time points, respectively.”

P1/2 data • Immunology • Rheumatoid Arthritis

Twenty-four weeks of treatment with a novel anti-IL-6 receptor nanobody (ALX-0061) resulted in 84% ACR20 improvement and 58% das28 remission in a phase I/II study in RA (EULAR 2013) - Presentation time: 13.06.2013; 10:50; Abstract #OP0043; P1/2, N=65; Sponsor: Ablynx; NCT01284569; "After 24 weeks of treatment, a total of 18 patients (58%) on ALX-0061 achieved DAS28 remission, of which 8 achieved Boolean remission. All DAS28 components contributed evenly and onset of remission occurred as early as week 2 for certain patients. Clinically meaningful improvements for bone oedema were observed and the global RAMRIS scores showed no worsening after 24 weeks."

P1/2 data • Immunology • Rheumatoid Arthritis

Results of a Phase IIb Study of Vobarilizumab, an Anti-Interleukin 6 Receptor Nanobody®, in Patients with Moderate-to-Severe Rheumatoid Arthritis Despite Treatment with Methotrexate (CRA-AHPA 2017) - "In patients with active RA despite methotrexate, treatment with vobarilizumab (150mg q4w, 150mg q2w and 225mg q2w) had a positive impact on disease activity with a compelling safety profile. A striking placebo effect was observed and is under investigation. Overall, the results support the advancement of vobarilizumab into phase III of development."

Adverse events • Clinical • P2 data • Biosimilar • Immunology • Rheumatoid Arthritis

Ablynx’s anti-IL-6R nanobody partnered with Abbvie demonstrates a bioavailability of more than 80% after subcutaneous injection (Ablynx Press Release) - P1, N=70; NCT02101073; Sponsor: Ablynx; "Ablynx...announced positive results from the Phase I bioavailability study of the subcutaneous formulation of its anti-IL-6R Nanobody®, ALX-0061, for the treatment of inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Bioavailability after subcutaneous administration was higher than 80% and there were no significant safety or tolerability signals noted with subcutaneous administration of ALX-0061."; Anticipated initiation of P2 studies with SC formulation in RA in early 2015 and in SLE by mid-2015; Anticipated results from the RA studies in H2 2016.

Anticipated new P2 trial • Anticipated P2 data • P1 data • Immunology • Lupus • Rheumatoid Arthritis

Ablynx to present additional data for its anti-IL-6R nanobody, vobarilizumab, a potential best-in-class treatment for rheumatoid arthritis (Ablynx Press Release) - "Ablynx...will present additional data from the Phase IIb RA combination study of...vobarilizumab, at the Annual Scientific Meeting of the Canadian Rheumatology Association...data show that in patients with active RA despite use of methotrexate, treatment with vobarilizumab (150mg q4w, 150mg q2w and 225mg q2w) had a positive impact on disease activity with a compelling safety profile."

Anticipated conference • Anticipated P2 data • Immunology • Rheumatoid Arthritis

Ablynx: FY 2015 Results (Ablynx) - Anticipated top-line data from P2b combination trial (NCT02309359) in rheumatoid arthritis in H2 2016; Anticipated top-line data from P2b monotherapy trial (NCT02287922) in rheumatoid arthritis in H2 2016; Anticipated top-line data from P2 open label extension study (NCT02518620) in rheumatoid arthritis in H2 2018; Anticipated initiation of P3 trial in rheumatoid arthritis in H2 2017

Anticipated new P3 trial • Anticipated P2 data • Anticipated P2b data • Immunology • Rheumatoid Arthritis

Ablynx: Clinical Trial Update (Ablynx) - "Vobarilizumab Phase IIb RA monotherapy study"; "Conclusions from topline results – week 12"; "Very encouraging efficacy data for vobarilizumab with ACR20, ACR50 and ACR70 scores of up to 81%, 49% and 24%, respectively"; "Rapid improvement in patients’ physical function based on the change from baseline in HAQ-DI score"; "Robust DAS28_CRP data for vobarilizumab with up to 60% of patients in either clinical remission or low disease activity at week 12 compared to 43% for open-label tocilizumab"; "Favourable safety profile at all administered doses"

P2b data • Immunology

Ablynx: HY 2015 Results (Ablynx) - Anticipated completion of enrollment of 558 patients from monotherapy P2b study (NCT02287922) and combination P2b study (NCT02309359) for RA by early 2016

Anticipated enrollment status • Immunology • Rheumatoid Arthritis

Vobarilizumab: Anticipated top-line data from P2 open label extension study (NCT02518620) for RA in H2 2018 (Ablynx) - Investor Presentation

P2 data • Immunology

Ablynx's anti-IL-6R nanobody, ALX-0061, shows excellent 24 week safety and efficacy results in a phase II clinical trial in rheumatoid arthritis (Ablynx) - P2, N=37; NCT01284569; Sponsor: Ablynx; The efficacy results ACR20, ACR50 & ACR 70 for the ‘unmodified’ pt population at week 24 found to be 75%, 63% & 50% with 1mg/kg Q4W & 100%, 75% & 63% with 3mg/kg Q4W whereas for 'modified' pt population is 75%, 50% and 50%. "A magnetic resonance imaging (MRI) assessment was also included in this study. At week 24, there was a reduction of bone oedema...global radiographic score confirmed the absence of disease progression at this final time point." Anticipated partnership for the development of ALX-0061

Anticipated licensing / partnership • P2 data • Immunology • Rheumatoid Arthritis

Ablynx: Corporate Presentation (Ablynx) - "Phase IIb combination therapy (+ MTX)"; "Up to 49% of patients in clinical remission at week 24"

P2b data • Immunology